Company profile
Reconnect Labs AG
Reconnect Labs is a Swiss, clinical stage biopharmaceutical company on a mission to disrupt the cycle of illness that underlies mental health conditions. Leveraging decades of expertise and a world-class network of leaders in clinical drug development, Reconnect Labs is progressing the development of rapid-acting precision psychiatry designed drug candidates with the potential to transform the treatment landscape for insomnia and psychiatric conditions such as PTSD and substance use disorders.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
